Anas Younes, MD, chief, Lymphoma Service, Memorial Sloan Kettering Cancer Center, discusses the future of treating lymphoid malignancies.
In a session at the 18th Annual International Congress on Hematologic Malignancies®
, oncologists discussed how to select patients with lymphoid malignancies for therapy in this era of molecularly-defined subsets of disease. Though tools exist to define mutations in certain diseases, they are not yet guiding therapy in lymphoid malignancies. Younes says he believes this is the future.
There remains a need to learn more about disease subsets and place patients in clinical trials to personalize treatments. This movement from treating all patients with R-CHOP to dissecting disease and offering treatments accordingly will represent a culture change.